(5R,7R,8S,9S,10R)-3-(2,3-Dihydrobenzo-1,4-dioxin-6-yl)-1,6-dioxa-7-(hydroxymethyl)-2-azaspiro[4.5]dec-2-ene-8,9,10-triol

ID: ALA3763976

Chembl Id: CHEMBL3763976

PubChem CID: 127026512

Max Phase: Preclinical

Molecular Formula: C16H19NO8

Molecular Weight: 353.33

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  OC[C@H]1O[C@@]2(CC(c3ccc4c(c3)OCCO4)=NO2)[C@H](O)[C@@H](O)[C@@H]1O

Standard InChI:  InChI=1S/C16H19NO8/c18-7-12-13(19)14(20)15(21)16(24-12)6-9(17-25-16)8-1-2-10-11(5-8)23-4-3-22-10/h1-2,5,12-15,18-21H,3-4,6-7H2/t12-,13-,14+,15-,16-/m1/s1

Standard InChI Key:  AVDNKXXKSPSFFF-IBEHDNSVSA-N

Alternative Forms

  1. Parent:

    ALA3763976

    ---

Associated Targets(Human)

PYGL Tchem Liver glycogen phosphorylase (1040 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Pygl Liver glycogen phosphorylase (81 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PYGM Glycogen phosphorylase, muscle form (1331 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 353.33Molecular Weight (Monoisotopic): 353.1111AlogP: -1.25#Rotatable Bonds: 2
Polar Surface Area: 130.20Molecular Species: NEUTRALHBA: 9HBD: 4
#RO5 Violations: 0HBA (Lipinski): 9HBD (Lipinski): 4#RO5 Violations (Lipinski): 0
CX Acidic pKa: 12.05CX Basic pKa: 2.10CX LogP: -0.81CX LogD: -0.81
Aromatic Rings: 1Heavy Atoms: 25QED Weighted: 0.52Np Likeness Score: 1.21

References

1. Goyard D, Kónya B, Chajistamatiou AS, Chrysina ED, Leroy J, Balzarin S, Tournier M, Tousch D, Petit P, Duret C, Maurel P, Somsák L, Docsa T, Gergely P, Praly JP, Azay-Milhau J, Vidal S..  (2016)  Glucose-derived spiro-isoxazolines are anti-hyperglycemic agents against type 2 diabetes through glycogen phosphorylase inhibition.,  108  [PMID:26708111] [10.1016/j.ejmech.2015.12.004]

Source